FR2684997A1 - Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique. - Google Patents

Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique. Download PDF

Info

Publication number
FR2684997A1
FR2684997A1 FR9115420A FR9115420A FR2684997A1 FR 2684997 A1 FR2684997 A1 FR 2684997A1 FR 9115420 A FR9115420 A FR 9115420A FR 9115420 A FR9115420 A FR 9115420A FR 2684997 A1 FR2684997 A1 FR 2684997A1
Authority
FR
France
Prior art keywords
sep
adenine
group
acetyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR9115420A
Other languages
English (en)
French (fr)
Inventor
Gosselin Gilles
Imbach Jean-Louis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9115420A priority Critical patent/FR2684997A1/fr
Priority to EP93902329A priority patent/EP0572644A1/de
Priority to CA002103884A priority patent/CA2103884A1/fr
Priority to PCT/FR1992/001182 priority patent/WO1993012128A1/fr
Priority to JP5510676A priority patent/JPH06505510A/ja
Publication of FR2684997A1 publication Critical patent/FR2684997A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FR9115420A 1991-12-12 1991-12-12 Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique. Withdrawn FR2684997A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR9115420A FR2684997A1 (fr) 1991-12-12 1991-12-12 Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.
EP93902329A EP0572644A1 (de) 1991-12-12 1992-12-14 9-(Beta-D-Xylofuranozyl)adenin und 1-(Beta-D-Xylofuranozyl)-Cytozinderivate, ihre Herstellung und ihre therapeutische Verwendung
CA002103884A CA2103884A1 (fr) 1991-12-12 1992-12-14 Derives de la 9-(b-d-xylofurannosyl)adenine et de la 1-(b-d-xylofurannosyl)cytosine, leur preparation et leur application en therapeutique
PCT/FR1992/001182 WO1993012128A1 (fr) 1991-12-12 1992-12-14 DERIVES DE LA 9-(β-D-XYLOFURANNOSYL) ADENINE ET DE LA 1-(β-D-XYLOFURANNOSYL)CYTOSINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JP5510676A JPH06505510A (ja) 1991-12-12 1992-12-14 ９−（β−Ｄ−キシロフラノシル）アデニンおよび１−（β−Ｄ−キシロフラノシル）シトシンの誘導体、それらの調製および治療薬への応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9115420A FR2684997A1 (fr) 1991-12-12 1991-12-12 Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
FR2684997A1 true FR2684997A1 (fr) 1993-06-18

Family

ID=9419960

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9115420A Withdrawn FR2684997A1 (fr) 1991-12-12 1991-12-12 Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.

Country Status (5)

Country Link
EP (1) EP0572644A1 (de)
JP (1) JPH06505510A (de)
CA (1) CA2103884A1 (de)
FR (1) FR2684997A1 (de)
WO (1) WO1993012128A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321784A (ja) * 1993-03-18 1994-11-22 Nippon Chemiphar Co Ltd 抗ヒト免疫不全ウイルス剤
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171518A1 (en) * 1995-03-24 1996-09-25 Douglas Patton Kjell Process for the preparation of 2,2'-anhydro- and 2' -keto-1-(3', 5'-di-o-protected-.beta.-d-arabinofuranosyl) nucleosides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
DE10110355A1 (de) 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
SG11201402826YA (en) 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6164M (de) * 1966-10-13 1968-07-08
DE2105560A1 (de) * 1971-02-06 1972-09-07 Boehringer Mannheim Gmbh, 6800 Mannheim Purinribonucleosid-Derivate und Verfahren zur Herstellung derselben
EP0098186A1 (de) * 1982-06-14 1984-01-11 Synthelabo Purin- oder Pyrimidinxyloside und -lyxoside enthaltende pharmazeutische Zusammensetzungen
EP0317728A2 (de) * 1987-09-22 1989-05-31 Warner-Lambert Company Verwendung von 9-(Beta-D-arabinofuranosyl)adenin-Derivaten zur Herstellung von Medikamenten zur Behandlung von AIDS
EP0322384A1 (de) * 1987-11-03 1989-06-28 Medivir Aktiebolag Nucleoside zur Verwendung für die Therapie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6164M (de) * 1966-10-13 1968-07-08
DE2105560A1 (de) * 1971-02-06 1972-09-07 Boehringer Mannheim Gmbh, 6800 Mannheim Purinribonucleosid-Derivate und Verfahren zur Herstellung derselben
EP0098186A1 (de) * 1982-06-14 1984-01-11 Synthelabo Purin- oder Pyrimidinxyloside und -lyxoside enthaltende pharmazeutische Zusammensetzungen
EP0317728A2 (de) * 1987-09-22 1989-05-31 Warner-Lambert Company Verwendung von 9-(Beta-D-arabinofuranosyl)adenin-Derivaten zur Herstellung von Medikamenten zur Behandlung von AIDS
EP0322384A1 (de) * 1987-11-03 1989-06-28 Medivir Aktiebolag Nucleoside zur Verwendung für die Therapie

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF CHEMISTRY. vol. 66, no. 5, 1988, OTTAWA CA pages 1258 - 1262; M.J.ROBBINS ET AL.: 'Nucleic Acid Related Compounds. 53. Synthesis and Biological Evaluation of 2'-deoxy-beta-threo-pentofuranosyl Nucleosides. "Reversion to Starting Alcohol" in Barton-type Reductions of Thionocarbonates' *
CHEMICAL ABSTRACTS, vol. 101, no. 23, 1984, Columbus, Ohio, US; abstract no. 207519, B.B.GOSWAMI ET AL.: 'Mechanism of Inhibition of Herpesvirus Growth by 2'-5'-Linked Trimer of 9-B-D-Xylofuranosyladenine' page 345 ;colonne 2 ; *
CHEMICAL ABSTRACTS, vol. 103, no. 25, 1985, Columbus, Ohio, US; abstract no. 215691G, G.GOSSELIN ET AL.: 'Synthesis of Arabinofuranonucleosides from Certain Xylofuranonucleosides' page 934 ;colonne 2 ; *
CHEMICAL ABSTRACTS, vol. 112, 1990, Columbus, Ohio, US; abstract no. 151297J, V.M.SHOBUKHOV ET AL.: 'A Comparative Study of Antiherpetic Effects of 9-B-D-Xylofuranosyladenine and 9-B-D-arabinofuranosyladenine and their Inhibitory Effect for HSV-1 with Abnormal Genome in Cell Culture' page 21 ;colonne 2 ; *
CHEMICAL ABSTRACTS, vol. 112, no. 11, 1990, Columbus, Ohio, US; abstract no. 99118K, A.NEUMANN ET AL.: 'Facile Synthesis of Anomerical Pure 9-(beta-D-xylofuranosyl) adenine.' page 809 ;colonne 2 ; *
CHEMICAL ABSTRACTS, vol. 66, 1967, Columbus, Ohio, US; abstract no. 83226Q, J.DE RUDDER ET AL.: 'Inhibitory Activity of 9-B-D-Xylofuranosyladenine on Herpes virus Multiplication in Cell Cultures' page 7782 ;colonne 2 ; *
CHEMICAL ABSTRACTS, vol. 75, no. 3, 1971, Columbus, Ohio, US; abstract no. 20873P, M.IKEHARA ET AL.: 'Nucleosides and Nucleotides. L. Purine Cyclonucleosides. 14. Synthesis and Properties of Cyclonucleosides Derived from 9-D-Xylofuranosyladenine' page 503 ;colonne 1 ; *
CHEMICAL ABSTRACTS, vol. 93, no. 1, 1980, Columbus, Ohio, US; abstract no. 10Y, R.I.GLAZER: 'Potentiation by 2'-Deoxycoformycin of the Inhibitory Effects of Cordycepin and Xylosyladenine on Nuclear RNA Synthesis in L1210 Cells' page 1 ;colonne 2 ; *
JOURNAL OF MEDICINAL CHEMISTRY. vol. 29, no. 2, 1986, WASHINGTON US pages 203 - 213; G.GOSSELIN ET AL.: 'Systematic Synthesis and Biological Evaluation of alpha- and beta-D-Xylofuranosyl Nucleosides of the Five Naturally Occurring Bases in Nucleic Acids and Related Analogues' *
JOURNAL OF ORGANIC CHEMISTRY. vol. 33, no. 4, 1968, EASTON US pages 1600 - 1603; E.J.REIST ET AL.: 'The Synthesi and Reactions of some 8-Substituted Purine Nucleosides' *

Also Published As

Publication number Publication date
JPH06505510A (ja) 1994-06-23
WO1993012128A1 (fr) 1993-06-24
CA2103884A1 (fr) 1993-06-13
EP0572644A1 (de) 1993-12-08

Similar Documents

Publication Publication Date Title
JP2728148B2 (ja) アミノアルギニンの分離および身体内の酸化窒素生成を遮断するための用途
JPH03236318A (ja) 抗うつ剤
US5385891A (en) Polysulfate of β-cyclodextrin derivative and process for preparing the same
FR2684997A1 (fr) Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.
EP0080818B1 (de) Erythromycin-B-Derivate
Baker et al. Prodrugs of 9-(. beta.-D-arabinofuranosyl) adenine. 2. Synthesis and evaluation of a number of 2', 3'-and 3', 5'-di-O-acyl derivatives
EP0080819B1 (de) 11-0-Alkylerythromycin A Derivate
JPH0393787A (ja) 抗ウイルス活性を有する薬剤、燐脂質誘導体及びその製造方法
US4691012A (en) Sialic acid derivative and process for preparing the same
HU199502B (en) Process for producing new purine derivatives and pharmaceutical compositions comprising same
FR2458556A1 (fr) Derives de la paromomycine, procede pour les preparer et leur usage comme medicament
Pennington et al. Streptohydrazid
JPH04202127A (ja) インターロイキン―１産生抑制剤
JPS5915886B2 (ja) ウイルス感染症の進展を阻止する獣医用薬剤
Rappoport et al. Preparation of L-Arabinose-1-C14 1
Shapira Synthesis of 5-Ethyluridine, a Model 5-Alkyl Substituted Pyrimidine Nucleoside1
Clavé et al. The Sulfo‐Click Reaction and Dual Labeling of Nucleosides
JPS6054960B2 (ja) 抗しゆよう性セプタシジン類似体
JP2663105B2 (ja) １４α−ヒドロキシ−４−アンドロステン−３，６，１７−トリオン水和物結晶及びその製造法
GB2211185A (en) Uridine derivatives and antiviral agents containing them
DE2421541A1 (de) Cyclisierte benzylidensaeuren
JP3195869B2 (ja) 新規ヌクレオシド誘導体
EP0656364A1 (de) Erythromycinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
Nogrady Potential Cytostatic Carbohydrate Derivatives. I. N-Mustard Urethans
Vorbrüggen et al. Nucleoside Syntheses, XXI. Synthesis of 5‐Methylaminomethyl‐2‐thiouridine, a Rare Nucleoside from t‐RNA

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse